US Patent Issued to NURIX THERAPEUTICS on April 14 for "Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway" (California Inventors)

ALEXANDRIA, Va., April 15 -- United States Patent no. 12,600,732, issued on April 14, was assigned to NURIX THERAPEUTICS INC. (San Francisco).

"Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway" was invented by Aileen Kelly (San Francisco) and Arthur T. Sands (San Francisco).

According to the abstract* released by the U.S. Patent & Trademark Office: "This disclosure relates to compounds useful for degrading BTK via a ubiquitin proteolytic pathway. The description also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders."

The patent was filed on March 10, 2023, under Application No. 18/120,341...